Compare GBIO & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBIO | COHN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 40.3M |
| IPO Year | 2020 | N/A |
| Metric | GBIO | COHN |
|---|---|---|
| Price | $5.66 | $17.50 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | ★ 93.6K | 79.0K |
| Earning Date | 03-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 5.87% |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.50 |
| Revenue | $15,270,000.00 | ★ $185,475,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.83 |
| Revenue Growth | N/A | ★ 107.11 |
| 52 Week Low | $3.00 | $6.10 |
| 52 Week High | $9.25 | $32.60 |
| Indicator | GBIO | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 45.53 |
| Support Level | $5.41 | $16.81 |
| Resistance Level | $5.72 | $22.29 |
| Average True Range (ATR) | 0.13 | 2.31 |
| MACD | 0.01 | -0.61 |
| Stochastic Oscillator | 78.38 | 7.99 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.